ClinicalTrials.gg
RecruitingNCT07787208Updated Aug 26, 2026

A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors

A Phase 1 interventional study of ONO-7429 in Solid Tumors, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 10 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is to evaluate the tolerability and safety of ONO-7429 in participants with unresectable advanced or recurrent solid tumors.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with or cytologically confirmed unresectable advanced or recurrent solid tumors.
  2. Participants who are or intolerant to standard therapy.
  3. Participants with Performance Status 0 or 1.
  4. Participants with tumor tissue samples available for biomarker testing.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a history or presence of severe to any other antibody agents.
  2. Participants with pericardial fluid, pleural effusion or ascites requiring treatment
  3. Participants with uncontrolled tumor-related pain
  4. Participants with severe peritoneal dissemination.
  5. Participants with multiple primary cancers.
  6. Participants with a history or presence of ILD or pulmonary fibrosis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    ONO-7429

    Drug: ONO-7429

Interventions

  • DrugONO-7429

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities(DLT)

    Time frame: From first dose through completion of the DLT evaluation period (approximately 21 days)

  2. Adverse event (AE)

    Time frame: Approximately 6 months

Secondary outcomes

  1. Area under the Plasma Concentration versus Time Curve (AUC)

    Time frame: Approximately 6 months

  2. Cmax

    Time frame: Approximately 6 months

  3. Tmax

    Time frame: Approximately 6 months

  4. Terminal elimination half-life(T1/2)

    Time frame: Approximately 6 months

  5. Ctrough

    Time frame: Approximately 6 months

  6. CL

    Time frame: Approximately 6 months

  7. Volume of distribution at steady state(Vss)

    Time frame: Approximately 6 months

  8. Objective Response Rate (ORR)

    Time frame: Approximately 6 months

  9. Disease Control Rate (DCR)

    Time frame: Approximately 6 months

  10. Best overall response(BOR)

    Time frame: Approximately 6 months

  11. Duration of Response (DOR)

    Time frame: Approximately 6 months

  12. Progression-Free Survival (PFS)

    Time frame: Approximately 6 months

  13. Overall Survival (OS)

    Time frame: Approximately 6 months

  14. Time to Response (TTR)

    Time frame: Approximately 6 months

  15. Percent change from baseline in the sum of diameters of target lesions

    Time frame: Approximately 6 months

  16. Best percent change from baseline in the sum of diameters of target lesions

    Time frame: Approximately 6 months

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jul 2028, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 26, 2026
StartActual
Jun 19, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Mar 2030
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07787208
Responsible party
Sponsor
First posted
Aug 26, 2026
Start date
Jun 19, 2026
Primary completion
Jul 2028 (estimated)
Completion
Mar 2030 (estimated)
Last update
Aug 26, 2026

Study contacts

North America Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+18665877745(Toll-Free)
International Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+17162141777(Standard)
Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion